David A. Siegel Humacyte, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 367,100 shares of HUMA stock, worth $635,083. This represents 0.0% of its overall portfolio holdings.
Number of Shares
367,100
Previous 44,600
723.09%
Holding current value
$635,083
Previous $76,000
909.21%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding HUMA
# of Institutions
168Shares Held
54.4MCall Options Held
1.1MPut Options Held
808K-
Black Rock Inc. New York, NY7.14MShares$12.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$12.1 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$7.6 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT3.43MShares$5.93 Million0.42% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$5.1 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $178M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...